Co-op, mRNA Process Development
Strand Therapeutics
Summary
Strand is looking for a highly motivated candidate to join as Co-op of the mRNA Process Development team at Strand Therapeutics to support the development, optimization, and scale-up of manufacturing processes for high-quality mRNA therapeutics. This role will provide hands-on experience with mRNA production, purification, analytical characterization, and process improvement activities in a collaborative and fast-paced biotechnology environment.
Job description
Job Summary
Strand is looking for a highly motivated candidate to join as Co-op of the mRNA Process Development team at Strand Therapeutics to support the development, optimization, and scale-up of manufacturing processes for high-quality mRNA therapeutics. This role will provide hands-on experience with mRNA production, purification, analytical characterization, and process improvement activities in a collaborative and fast-paced biotechnology environment.
Primary Responsibilities
- Execute experiments related to the advancement of Strand's mRNA manufacturing and/or process optimization platforms.
- Carry out the production of IVT synthesized mRNA.
- Support screening, optimization, and scale-up efforts for enzymatic reactions, chromatographic separations and filtration processes - including ultrafiltration, diafiltration, and sterile filtration.
- Perform analytical assays and characterization studies to evaluate mRNA quality and process performance.
- Analyze experimental data and contribute to technical presentations, reports, and team discussions.
- Maintain accurate and detailed experimental records in electronic laboratory notebooks.
- Work effectively to support the group's development activities in a fast-paced and collaborative environment.
Qualifications
- Currently pursuing a B.S. or M.S. in Biochemistry, Chemical Engineering, Molecular Biology, Bioengineering, Molecular Medicine, Genetics or related field. Experience in the biotechnology space is a plus.
- Experience with nucleic acid workflows, chromatography, filtration processes, or biological analytic techniques is preferred, but not required.
- Ability to follow standard operating procedures, make careful observations, maintain clear and complete records of lab work.
- Strong collaboration and inter-personal skills. Ability to present scientific context, experimental set up, data interpretation, and big-picture conclusions to a diverse audience.
Requirements
- Currently pursuing a B.S. or M.S. in Biochemistry, Chemical Engineering, Molecular Biology, Bioengineering, Molecular Medicine, Genetics or related field
- Experience in the biotechnology space is a plus
- Experience with nucleic acid workflows, chromatography, filtration processes, or biological analytic techniques is preferred, but not required
- Ability to follow standard operating procedures, make careful observations, maintain clear and complete records of lab work
- Strong collaboration and inter-personal skills
- Ability to present scientific context, experimental set up, data interpretation, and big-picture conclusions to a diverse audience
Company overview
Strand Therapeutics is a pioneering biotechnology company founded in 2017 by researchers from MIT's Synthetic Biology Center. The company is developing the world's first platform for creating programmable, long-acting mRNA therapeutics capable of delivering precise, multi-functional, and potentially curative treatments. Strand's innovative approach involves embedding mRNA therapeutics with sophisticated genetic logic circuits that enable them to identify specific cell types and activate only in diseased cells, while remaining inactive in healthy tissues. This technology dramatically increases the therapeutic window and safety profile of mRNA medicines. The company's proprietary mRNA programming language allows for precise control over the location, timing, intensity, and duration of protein expression, representing a significant advancement in synthetic biology applications for medicine. Strand is currently advancing a pipeline of programmable mRNA therapeutics focused on cancer and other life-threatening diseases, with their lead candidate STX-001 already in Phase 1 clinical trials for solid tumors. The company has raised over $256 million in funding from prominent investors including Kinnevik, Regeneron, Eli Lilly, and Amgen.